Sylvatica Biotech

Executive Summary

Sylvatica Biotech is addressing the critical unmet need in organ and tissue preservation, which imposes severe logistical constraints on transplantation, regenerative medicine, and drug discovery. Founded in 2019 and based in San Diego, the company aims to develop innovative preservation technologies that extend the viable storage time of organs and tissues, thereby expanding the donor pool, improving transplant outcomes, and enabling on-demand availability for biomedical research. By leveraging cutting-edge approaches in cell biology and cryopreservation, Sylvatica seeks to overcome the current limitations of static cold storage, which typically allows only 4–6 hours for heart and lung transplants. Success could transform healthcare, saving or improving millions of lives annually and reducing healthcare costs associated with organ failure.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round70% success
• Q2 2027Partnership with Major Transplant Center60% success
• Q1 2027Preclinical Proof-of-Concept Data in Large Animal Model75% success